Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026 Enrollment in RAPIDe-3, the ...
Alector (ALEC) highlighted recent progress and strategic priorities for 2025. Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain ...